Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Oral NA-931, Alone or in Addition to Open Label Subcutaneous Tirzepatide , to Investigate the Efficacy and Safety in Overweight or Obese Men and Women

NCT06732245 is registered in ClinicalTrials.gov with Biomed Industries, Inc. as lead sponsor.

NCT NCT06732245
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06732245 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Oral NA-931, Alone or in Addition to Open Label Subcutaneous Tirzepatide , to Investigate the Efficacy and Safety in Overweight or Obese Men and Women
Lead sponsor
Biomed Industries, Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 15, 2026
Completion date
December 15, 2027
Enrollment
224 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

obesity and overweight